Online inquiry

IVTScrip™ pT7-VEE-mRNA-Anti-PRLR, ABBV-176 Vector   (CAT#: GTVCR-WQ151MR)

This product GTVCR-WQ151MR is an effective transcription system suitable for a variety of research, including the in vitro translation, self-amplifying mRNA studies and protein expression. The system was driven by the T7 promoter to efficiently generate mRNA ecoding antibody which targeting PRLR. The vector contains the self-replicating Venezuelan equine encephalitis (VEE) virus RNA replicon, which resulting the mRNA expression at a high level.

SPECIFIC INQUIRY

3' poly(A):
Inquiry
Specifications
Product type Vector
Promoter T7
Resistance Ampicillin
Species Chimeric
RefSeq NM_000949.7
Applications IVT; Self-amplifying mRNA (SAM) research; Gene therapy research
Format Solution
Concentration 1 µg/µl
Quantity 10 µg
Target Gene
Gene ID 5618
UniProt ID P16471
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ pT7-VEE-mRNA-Anti-PRLR, ABBV-176 Vector (GTVCR-WQ151MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTVCR-WQ377MR IVTScrip™ pSP6-VEE-mRNA-Anti-IL15, ALT-803 Vector Vector ALT-803
GTVCR-WQ1625MR IVTScrip™ pSP6-VEE-mRNA-Anti-KLRK1, JNJ-64304500 Vector Vector JNJ-64304500
GTVCR-WQ2092MR IVTScrip™ pT7-VEE-mRNA-Anti-MUC5AC, NOE-102 Vector Vector NOE-102
GTVCR-WQ1462MR IVTScrip™ pSP6-VEE-mRNA-Anti-F3, HuMax-TF-ADC Vector Vector HuMax-TF-ADC
GTVCR-WQ2513MR IVTScrip™ pSP6-VEE-mRNA-Anti-CSF1R, SNDX-6352 Vector Vector SNDX-6352
GTVCR-WQ2339MR IVTScrip™ pT7-VEE-mRNA-Anti-GP, REGN-3470-3471-3479 Vector Vector REGN-3470-3471-3479
GTVCR-WQ311MR IVTScrip™ pT7-VEE-mRNA-Anti-CFD, AFD Anti-fD Vector Vector AFD Anti-fD
GTVCR-WQ882MR IVTScrip™ pT7-VEE-mRNA-Anti-Factor IX substitute, CB 2679d Vector Vector CB 2679d
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW